schizophrenia gene therapy (Pfizer)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug Nameschizophrenia gene therapy (Pfizer)
Drug Alias Namebipolar disorder gene therapy (Pfizer)schizophrenia gene therapy (Axys/Parke-Davis)bipolar disorder gene therapy (Axys/Parke-Davis)
ClassificationCell and gene therapy > Gene therapy
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsSchizophreniaBipolar Disorder
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesCelera
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesParke-Davis CorpCelera
Active IndicationsN/A
Inactive IndicationsSchizophreniaBipolar Disorder

Other Information

ATC CodeN/A
Related LinksN/A